1. Life Sciences industry remains strong, but some big name companies face layoffs — Merck pulls Keytruda's SCLC nod — Novavax counting on vaccine EUA in US by May See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

Latest News - ADU won't be approved

Discussion in 'BiogenIdec' started by anonymous, Oct 19, 2020 at 9:26 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest


    Facts and data are the deciding factor, not emotion. The FDA report on Wednesday was choke full of inappropriate emotional narrative style writing as if they worked directly with the Biogen team. The AdComm panel destroyed the FDA for this. The head of Neurology at the FDA absolutely embarrassed himself multiple occasions yesterday acting like a shill for Biogen. Someone needs to check his family members work at an investment firm or heavily bought stock, it was that bad. There is no way the FDA can approve this after such a strong and emphatic NO from the Committee.
     

  2. anonymous

    anonymous Guest

    What was up with Biogen making offers on Friday to the Wave 2 people BEFORE the end of the day and knowing how the AdComm was going to vote??
     
  3. anonymous

    anonymous Guest


    *not knowing
     
  4. anonymous

    anonymous Guest

    Calling the Advisory Committee's verdicts a "near unanimous vote against aducanumab and strong commentary against the FDA's own analyses," Kasimov warns that "with the FDA's reputation already in a precarious position, it could be difficult -- maybe impossible -- to go against an expert panel at this time no matter how badly they want this."
     
  5. anonymous

    anonymous Guest

    FDA's Bill Dunn is planning on leaving FDA? His comments prior to the advisory committee meeting took Biogen to 15 Billion. Hmmmm
     
  6. anonymous

    anonymous Guest

    On Law & Order, they’d be looking at his checking account for recent large deposits.
     
  7. anonymous

    anonymous Guest

    Good bye !!!
    Will there be a severance package??
     
  8. anonymous

    anonymous Guest

    This doesn't sound right. There are several other Alzheimer's drugs in the pipeline now so pushing this out without adequate evidence on both efficacy and safety would be scientifically very irresponsible. The most reasonable thing to do is proceed with a second phase 3 trial to ultimately prove the efficacy is reproducible or not.
     
  9. anonymous

    anonymous Guest

    Why is Biogen's leadership so super confident they are getting approval?
     
  10. anonymous

    anonymous Guest

    Desperation.
     
  11. anonymous

    anonymous Guest

    What is Biogen going to promote with no Adu? Interferon?
     
  12. anonymous

    anonymous Guest

    You would have to have Alzheimer’s to take this job now
     
  13. anonymous

    anonymous Guest

    I heard Biogen just bought Aspirin XL for 300 million dollars? FDA will fast track, Biogen strong!!
     
  14. anonymous

    anonymous Guest

    #biogenchokesthechicken
     
  15. anonymous

    anonymous Guest

    For the well being of ALL patients, just do the additional phase 3 trial It needs to be done and should not be approved until so.
     
  16. anonymous

    anonymous Guest

    Arrogance meets karma and she is a bitch! Too bad so sad
     
  17. anonymous

    anonymous Guest

    Talk about karma for the arrogant knuckleheads who dissed the good folks who got laid off in 2018 and 2015. A lot of these went to Adu. Karma is a bitch. Never diss anyone as we all can be in this situation and might need their help in future. For those who did the dissing learn this lesson!
     
  18. anonymous

    anonymous Guest

    This couldn’t have been played any worse. These people are embarrassing.